Global Primary Sclerosing Cholangitis Market 2019: Covering Competitive Scenario And Dynamics By Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others

These organizations have new business techniques which will be the snapshot of effect for change the Primary Sclerosing Cholangitis market. Accordingly, the Primary Sclerosing Cholangitis market research report is encased with all the organization profiles that you have to know to pick up an advantage from the market. This report clarifies the importance of the definition, characterizations, applications, and commitment while elucidating the players’ activities regarding their item dispatches, inquiries about, joint endeavors, mergers, and allegations. The Primary Sclerosing Cholangitis market report contains market key drivers and restrictions by utilizing the SWOT examination.

This report presents the organization profiles that prove to be in the competitor for the Primary Sclerosing Cholangitis market. With the assistance of SWOT analysis, this report illuminates you pretty much all the market control and drivers to be followed in the estimate years 2019-2026 while clarifying the Primary Sclerosing Cholangitis market’s definition, characterizations, applications, and commitment. A fastidious examination of components affecting the speculation is likewise given which figures out looming opportunities to the organizations and builds up the procedures to support the rate of profitability.

Market Analysis: Global Primary Sclerosing Cholangitis Market 

Global Primary Sclerosing Cholangitis Market is expected to rise gradually to an estimated value of USD 157.13 million by 2026, registering a CAGR of 3.7% in the forecast period of 2019-2026 with the annual sales of USD 117.5 million in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Ask For Complimentary Sample PDF | Request At

Key Market Competitors: Global Primary Sclerosing Cholangitis Market 

Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.

Market Drivers

Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.

Large No. of pipeline molecules is expected to drive the growth of the market.

Market Restraints

Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.

Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.

Lack of skilled expertise in remote areas

Fewer Government initiatives taken in this direction.

Table of Contents


1.Market Segmentation

2.Market Overview

3.Executive Summary

4.Premium Insights

5.Global, By Component

6.Product Type


8.Industry Type


Get detailed toc @

Segmentation: Global Primary Sclerosing Cholangitis Market 

By Type

Classic PSC

Small-duct PSC

PSC associated with autoimmune hepatitis

By Treatment Type

Ursodeoxycholic acid

Obeticholic Acid




By Symptom Control




Opioid Antagonists



By End- User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America




South America



Rest of South America




United Kingdom








Rest of Europe




South Korea








Rest of Asia Pacific

Middle East & Africa

South Africa


Saudi Arabia

United Arab Emirates


Rest of Middle East & Africa

Key Developments in the Market:

On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.

On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.

Competitive Analysis: Global Primary Sclerosing Cholangitis Market 

Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Inquiry For Customize Report With Discount at :

Customization of the Report:

All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


Data Bridge Market Research

Tel: +1-888-387-2818







Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *